11 episodes

Highlights and interviews from the 2017 ESMO conference on gastrointestinal cancer.

ESMO GI 2017 ecancer

    • Medicine

Highlights and interviews from the 2017 ESMO conference on gastrointestinal cancer.

    • video
    Implementation of a wait and see program for rectal cancer

    Implementation of a wait and see program for rectal cancer

    Prof D’Hoore talks to ecancer at ESMO GI 2017 about the implementation of a wait and see program for rectal cancer, and the possible pitfalls.

    He discusses the use of endoscopy, imaging and PET scanning for diagnosis, and the challenges of avoiding radical surgery and opting for a "watch and wait" protocol.

    Finally, he discusses the highlights of ESMO GI 2017.

    • 3 min
    • video
    Left versus right in colon cancer

    Left versus right in colon cancer

    Dr Grothey talks with ecancer at ESMO GI 2017 about the value of sidedness in colon cancer. He discusses how the location of the tumour can affect how the cancer responds to different drugs and treatments. He goes on to discuss his thoughts on drug prescription, dependant on tumour location.

    • 2 min
    • video
    The GI oncologist of the future

    The GI oncologist of the future

    Dr Grothey talks with ecancer at ESMO GI 2017 about what the future holds for GI oncologists. He states that he believes that the way that oncologists interact with patients will change to allow patients to have access to medical information and their care throughout the entire process. Dr Grothey believes that there will be a device created to transmit information, continuously, between patient and medical professional, allowing treatments to be modified early if needed.

    Dr Grothey goes on to discuss immunotherapies and how he thinks there will be inroads made into treating cancers that are not currently immunogenic. He believes that immunotherapy will be used as first line treatment.

    Dr Grothey then talks about how he believes that diagnostic tools will be developed to allow circulating markers to be more evident through the diagnostic process.

    • 3 min
    • video
    Minimally invasive surgery for cancer of the oesophagus

    Minimally invasive surgery for cancer of the oesophagus

    Prof Mariette talks with ecancer at ESMO GI 2017 about a phase III randomised trial, looking at minimally invasive oesophagectomy and the benefits of this procedure over open oesophagectomy. He goes on to outline the benefits of using laparoscopic gastric mobilisation and open thoracotomy over the standard opened abdominal and open thoracic approach.

    • 2 min
    • video
    New evolutions for the neoadjuvant and adjuvant treatment of oesophageal cancer

    New evolutions for the neoadjuvant and adjuvant treatment of oesophageal cancer

    Prof Lordick talks with ecancer at ESMO GI 2017 about news and new evolutions for neoadjuvant and adjuvant treatment of oesophageal cancer. He discusses the new ESMO guidelines for oesophageal cancer and talks about the need to separate recommendations for oesophageal cancer and adenocarcinoma because of the different biology of the diseases.

    • 3 min
    • video
    Neo-adjuvant/adjuvant treatment in gastric cancer

    Neo-adjuvant/adjuvant treatment in gastric cancer

    Dr Chau talks with ecancer at ESMO GI 2017 about the optimal approach to neo-adjuvant/adjuvant treatment in gastric cancer in 2017.

    He discusses the uses multi-modality treatments such as pre-operative treatments and post-operative treatments, and the survivorship outcomes within different regions.

    • 2 min

Top Podcasts In Medicine

More by ecancer